A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q33392683

about

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia.A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.Expanding role of lenalidomide in hematologic malignancies Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.Acute myeloid leukemia in the real world: why population-based registries are needed.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia Salvage therapy for relapsed or refractory acute myeloid leukemia Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).Upfront therapy of acute myeloid leukemia.Novel and emerging drugs for acute myeloid leukemia Lenalidomide as a novel treatment of acute myeloid leukemia.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities.The safety of treatment options for elderly people with acute myeloid leukemia.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy.Recent developments in management of older patients with acute myeloid leukemia.Trial Watch: Lenalidomide-based immunochemotherapy.

P2860

Q27851686-E5E75B1C-8F82-4BC2-8857-D336CFB6E9AE Q33405278-21BF9E86-1489-4A6C-96C1-8B9804BCA68C Q33414087-84E48E97-0234-43BA-8F59-23540158DDE0 Q33434768-C5295BF5-9EF6-4672-A38A-5BF3D685FD52 Q33574178-18769701-D9B7-4256-B618-7CFEF0DB4D1B Q33595548-AD413D9A-F65F-4860-A682-4B0E82C04B0E Q33919884-16112348-5C4A-48A7-802A-77CB70198251 Q34060237-25948870-53E8-41F7-9C4D-B049794B43DE Q34342944-B8D2DE87-786A-4F6B-8837-BDF9BFD67F2A Q35082495-38298BFC-14EE-436B-9575-FE2848AC6B12 Q35125889-C229D3C5-695F-4654-8EB6-EC8C178FB308 Q35592305-85AB27C2-F85A-4F7D-B18E-50E400ADCAF5 Q35651754-391EDD83-2E1F-4A6C-BBBC-EEDBD11BA8E4 Q35881223-1C25BD1C-D9DE-4736-900E-9A83EF856AEF Q35980291-E8B8D260-45EE-4D6D-B3C8-60BABA818986 Q36474572-956E54BB-1E7F-4BC7-A245-C9AD591996B1 Q36512601-23111A12-C7E3-48CB-8FF0-E5B87DAD96A0 Q36612564-DB0D9416-CA78-4D90-A4DC-507FCE440225 Q36804633-8B919CE0-6E60-469B-BA00-D62B56224CA7 Q36862505-3B920854-0443-450A-A333-217EAE107558 Q37074311-584976D4-45B4-4173-ABAA-ACCAA134F578 Q37672544-12E08728-59AC-46E4-BA9A-B8B779644F07 Q37897183-EE79FF10-C121-42E9-932B-409A3BA154A0 Q38000711-03514AB0-367C-48C3-8CDE-43D243123F70 Q38073811-698FACE0-4850-432D-ABE7-FF87DDB0CF00 Q38104287-02CCF539-37FF-4DA2-996B-4ECAFAB5B8FC Q38115584-981CB4EE-C133-4F00-A521-4448415B7A57 Q38161965-3AE54D86-2BC5-4507-86C1-7E5DD3A8F129 Q38250205-0459C167-57B7-49E1-B3FD-D29D8638A0AC Q38542828-337A46EB-8AB6-4FED-93F5-41842E9B75EF Q38676390-7C55B256-D6A6-4E1B-9414-1617D1283DD0 Q38760822-39AEDAD4-FBA2-44C1-8523-F18ACF570E46 Q38843235-146CE61A-9D8E-429C-868B-65498DF75646 Q38874826-D47D5763-CEE2-40CD-92ED-BCF2B0E42173 Q39205106-06264BBC-562B-45BB-BF83-60B51EE95CBC Q39240258-1B82375B-DDB6-45CB-9E49-B914A53334FD Q41573313-A8C4F663-EA56-4848-8D1B-4CC3C92A1B3C Q41891342-898CCE1F-824A-4B8D-9FA2-ABC148D159C4 Q42149211-3A51FEEB-4C76-4915-BFFB-6F5B55DE82D5 Q42737828-3D969EEE-12EE-4D1F-9959-A67C64E8A266

P2860

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

http://www.wikidata.org/entity/Q33392683

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@ast

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@en

type

label

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@ast

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@en

prefLabel

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@ast

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@en

P1433

Q33392683-546B141F-253F-4455-9820-290D5984D80B

P1476

Q33392683-06B88071-42BF-42AB-BBEF-D4559371301A

P2093

Q33392683-03222219-63DD-45A4-9A27-8A77A72D427F

Q33392683-16E12CE1-610B-4B73-8FCF-B05BAD085F82

Q33392683-481CE615-19DE-4011-B332-64A4E522C31C

Q33392683-6AE48EF5-778B-4DCB-ACBD-C58A7ECB63C8

Q33392683-8DD2AFBA-1A9F-42EA-92E2-5D126D4A2668

Q33392683-928A44A1-687C-4932-805C-F510C0F3918A

Q33392683-A527AEA7-DA44-48A8-9EDF-806C5313D287

Q33392683-B766344F-E1B1-4ECE-8D05-8DFD3C0A9E7B

Q33392683-C15A183D-0319-43BF-9F88-DEBC7938EF0C

P2860

Q33392683-08D89178-DAB4-4836-9E97-871E5EB43CD4

Q33392683-12075955-D904-422A-B19C-3C11FD5FEEAC

Q33392683-279F874A-A455-40C9-B119-490B857402E1

Q33392683-27E90DFB-A412-4918-8DF6-6552497A562F

Q33392683-284C1687-333F-4DA5-827C-982B7B875A91

Q33392683-4562C4A7-22CF-43AC-9755-D49FF4EAF715

Q33392683-58687F04-2129-4C14-9344-77137B499A28

Q33392683-5D0396CE-86DA-4FCC-9743-F72B02D78CEE

Q33392683-5EBA242D-3EC6-4EC8-AD96-CA61C4EB30E9

Q33392683-5EC1C220-A45F-46FC-B500-BAD6411D5689

P304

Q33392683-66C77FD0-0456-4FC7-B6DD-0105F1E92A7D

P31

Q33392683-251682FF-C201-4484-8406-010AEB91370E

P356

Q33392683-6CCEB526-8CF1-4E25-A51D-C3C0142C6930

P407

Q33392683-40306C13-204C-456A-95AA-27A0AC8C5242

P433

Q33392683-09F6C40A-AAFA-4BE0-B8A9-0DA8F01009E9

P478

Q33392683-FA6E798E-368D-4A0C-8D57-904E039A61E0

P50

Q33392683-0FAB56C5-28BE-43B9-A6FB-0A34A295DF2A

Q33392683-ADE243D0-B4B8-4B2D-83C7-BE6EB684CC15

P577

Q33392683-FAD549AE-A16E-42A9-818D-52EFE8B4E08E

P5875

Q33392683-FBC5064E-9E48-4144-A241-F89A8C28FCAB

P698

Q33392683-73AA3F58-4F88-4A2B-8353-FF10D3BE711B

P921

Q33392683-009217BD-9781-43BE-90EB-5E80D87A6C02

P932

Q33392683-5270455C-3BDF-40AF-B57F-F85CD89D7ECF

P356

BLOOD-2010-07-297143

P1433

P1476

A phase 2 study of high-dose l ...... s with acute myeloid leukemia.

@en

P2093

Alissa D Nelson

http://www.w3.org/2001/XMLSchema#string

Amanda F Cashen

http://www.w3.org/2001/XMLSchema#string

Camille N Abboud

http://www.w3.org/2001/XMLSchema#string

Jeffery Demland

http://www.w3.org/2001/XMLSchema#string

John F DiPersio

http://www.w3.org/2001/XMLSchema#string

Kathryn Trinkaus

http://www.w3.org/2001/XMLSchema#string

Keith E Stockerl-Goldstein

http://www.w3.org/2001/XMLSchema#string

Peter Westervelt

http://www.w3.org/2001/XMLSchema#string

Ravi Vij

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

P304

1828-1833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-07-297143

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Todd A Fehniger

P577

2010-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47679136

http://www.w3.org/2001/XMLSchema#string

P698

21051557

http://www.w3.org/2001/XMLSchema#string

P921

P932

3318598

http://www.w3.org/2001/XMLSchema#string